2010
DOI: 10.1016/j.bcp.2009.11.018
|View full text |Cite
|
Sign up to set email alerts
|

Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model

Abstract: Evidence for the important role for poly(ADP-ribose) polymerase (PARP) in the pathogenesis of diabetic nephropathy is emerging. We previously reported that PARP inhibitors counteract early Type 1 diabetic nephropathy. This study evaluated the role for PARP in kidney disease in long-term Type 1 diabetes. Control and streptozotocin-diabetic rats were maintained with or without treatment with the PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2-diaza-benzo[de] anthracen-3-one (GPI-15,427, Eisai Inc.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
21
1

Year Published

2011
2011
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(23 citation statements)
references
References 67 publications
1
21
1
Order By: Relevance
“…Benzamide has been shown to be an endogenous inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) [25,26], a key enzyme that has been strongly implicated in causing diabetes-associated endothelial dysfunction [27]. Pharmacological inhibition of PARP-1 ameliorated various features associated with nephropathy in both experimental models of type 1 and type 2 diabetes, including albuminuria [28,29]. Urinary albumin and protein excretion were reduced in the streptozotocin-diabetic mouse model with the endogenous Parp1 gene constitutively ablated by gene knockout [30].…”
Section: Discussionmentioning
confidence: 99%
“…Benzamide has been shown to be an endogenous inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) [25,26], a key enzyme that has been strongly implicated in causing diabetes-associated endothelial dysfunction [27]. Pharmacological inhibition of PARP-1 ameliorated various features associated with nephropathy in both experimental models of type 1 and type 2 diabetes, including albuminuria [28,29]. Urinary albumin and protein excretion were reduced in the streptozotocin-diabetic mouse model with the endogenous Parp1 gene constitutively ablated by gene knockout [30].…”
Section: Discussionmentioning
confidence: 99%
“…NAD ϩ depletion and energy failure can be induced by ROS-trigged PARP activation. PARP inhibition (INO-1001, PJ34, 1,5-isoquinolinediol, and GPI-15,427) and PARP-1 gene deficiency are examples of nephroprotection (9,40,41,43). Moreover, a higher NAD or NAD ϩ /NADH ratio can activate the sirtuin 1 (SIRT1) pathway (3,47), which is a known renal cytoprotector responding to aging and stress (51).…”
Section: Discussionmentioning
confidence: 99%
“…Indeed, PARP-1 and other PARP family members have proven to be effectively inhibited by a broad array of small molecules (Rouleau et al 2010). The therapeutic application of PARP inhibitors has received a considerable amount of attention recently because of their potential utility in the treatment of cancers, but the possible therapeutic applications of PARP inhibitors extend far beyond cancer therapy to other types of stress-related diseases, such as cardiovascular diseases, stroke, metabolic disorders, diabetes, and autoimmunity, and virtually any disease or condition with acute or chronic inflammation as a root cause (Masutani et al 2005;Mota et al 2005;Pacher and Szabo 2007;Shevalye et al 2010;Ford and Lee 2011;Underhill et al 2011).…”
Section: Therapeutic Applications Of Parp Inhibitorsmentioning
confidence: 99%
“…In this regard, PARP inhibitors have been explored as therapeutics to prevent cell death, tissue damage, and dysfunction associated with aging-or oxidative damage-related pathologies, such as cardiovascular diseases, autoimmune and inflammatory diseases, neurodegenerative diseases, stroke, and diabetes and its associated complications ( Fig. 7; Masutani et al 2005;Mota et al 2005;Pacher and Szabo 2007;Shevalye et al 2010;Ford and Lee 2011;Underhill et al 2011). The recent discovery of the metabolic functions of PARP-1 and PARP-2, in concert with SIRT1, based on knockout mouse models suggests a therapeutic potential of PARP inhibitors in metabolic disorders (Bai et al 2011a,b).…”
Section: Parp Inhibitors and The Treatment Of Cancersmentioning
confidence: 99%